Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2018 18:40 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin

IRVING, Texas, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that it has received a $30 million milestone...
August 08, 2018 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs

IRVING, Texas, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development...
August 06, 2018 17:35 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018

IRVING, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call...
July 27, 2018 11:05 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVING, Texas, July 27, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
July 24, 2018 20:52 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering

IRVING, Texas, July 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering...
July 23, 2018 16:39 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

IRVING, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to...
July 23, 2018 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease

Statistically Significant Improvement in Kidney Function Maintained in Alport Syndrome Patients After 48 Weeks of Treatment Statistically Significant Retained Benefit of 4.1 mL/min in Alport Syndrome...
July 10, 2018 16:18 ET | Source: Reata Pharmaceuticals, Inc.

Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich’s Ataxia

IRVING, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission has granted...
June 20, 2018 16:18 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt

IRVING, Texas, June 20, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of...
June 14, 2018 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility

IRVING, Texas, June 14, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered...